ReviewJournal of general internal medicine2018
Diagnosis and Management of Hepatitis C Infection in Primary Care Settings.
Review in Journal of general internal medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 63 citations in OpenAlex.
- Identifying Varying Influences on Eliminating Hepatitis C Across Medical Specialties.Journal of viral hepatitis · 2025Article
- The Impact of COVID-19 and Related Public Health Measures on Hepatitis C Testing in Ontario, Canada.Viruses · 2025Article
- Detection of anti-HCV antibodies in the clinical classification and epidemiological surveillance of HCV infection.Molecular biology reports · 2025Review
- Hepatitis C-Everything a Primary Care Physician Needs to Know About Diagnosis, Management, and Follow-Up.Journal of clinical medicine · 2025Review
- No Time to Wait: Leveraging Primary Care to Treat Stimulant Use Disorder.American journal of preventive medicine · 2024Article
- Real-world Experiences in the Transplantation of Hepatitis C-NAAT-positive Organs.Transplantation direct · 2023Article
- Expression ofMedicina (Kaunas, Lithuania) · 2023Article
- Review
- Uptake of hepatitis C direct-acting antiviral treatment in China: a retrospective study from 2017 to 2021.Infectious diseases of poverty · 2023Article
- Reliving it All Over Again: Uncanny Temporalities of Injection Drug Use and Hepatitis C Diagnosis in Southwest Virginia, USA.Medical anthropology · 2023Article
- Hepatitis C virus seroprevalence among patients enrolled at the opioid substitution therapy center in Bihar: A cross-sectional study.PloS one · 2023Article
- Integrating Management of Hepatitis C Infection into Primary Care: the Key to Hepatitis C Elimination Efforts.Journal of general internal medicine · 2022Review
- Changes in Hepatitis C Awareness in Different Disciplines During COVID-19.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2022Article
- Physician- and patient-reported barriers to hepatocellular carcinoma surveillance: A nationwide survey.Medicine · 2022Article
- Hepatitis C virus (HCV) seroprevalence, RNA detection, and genotype distribution across Florida, 2015-2018.Preventive medicine · 2022Article
- Management of in- and out-of-hospital screening for hepatitis C.Frontiers in public health · 2022Review
- Prevalence of HCV Infection Among Hemodialysis Patients in Lanzhou of Northwestern China.Infection and drug resistance · 2022Article
- Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021Observational
- Decreases in Hepatitis C Testing and Treatment During the COVID-19 Pandemic.American journal of preventive medicine · 2021Article
- Sofosbuvir/Velpatasvir - A Promising Treatment for Chronic Hepatitis C Virus Infection.Cureus · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis C virus (HCV) infection is a significant health problem worldwide, and is the leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation in the United States. The management of HCV has changed significantly over the last 5 years, as treatments have become simpler and more efficacious. Medication efficacy is now greater than 90%, with a high barrier to resistance and few side effects. This review is a collaboration between primary care and hepatology providers to explore all aspects of HCV management: acute versus chronic HCV infection, transmission and testing, and diagnosis and treatment. Specific medications for the treatment of HCV infection are considered, and patient and medication factors including genotype, liver disease status, and comorbidities affecting medication choice are discussed. This is a new era for the management of HCV infection, and interested primary care physicians, family doctors, and general internists can be at the forefront of diagnosis, management, and treatment of HCV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.